恩那度司他治疗非透析CKD贫血的3期研究:SYMPHONY ND
SYMPHONY ND研究在非透析CKD贫血患者中比较口服恩那度司他与达依泊汀α。主要终点为第20-24周平均Hb差异,恩那度司他组为10.96 g/dl,组间差异0.09 g/dl(95%CI -0.07至0.26),达到非劣效。两组不良事件发生率无明显差异,未发现新安全性信号。
要点
- 恩那度司他对比达依泊汀α在非透析CKD贫血患者中Hb维持非劣效。
- 第20-24周平均Hb组间差异0.09 g/dl(95%CI -0.07至0.26)。
- 恩那度司他降低铁调素和铁蛋白,升高总铁结合力。
核心结论
- 在非透析CKD贫血患者中,恩那度司他疗效与达依泊汀α相当,未发现新的安全性问题。
研究设计与样本
- 3期随机对照研究,纳入日本非透析CKD贫血患者,ESA未治与ESA治疗患者分别1:1随机至口服恩那度司他每日一次或皮下达依泊汀α每2或4周一次,治疗24周。
- 每4周调整剂量以维持Hb在10-12 g/dl目标范围,主要终点为第20-24周两组平均Hb差异,非劣效界值-0.75 g/dl。
主要发现
- 恩那度司他组评估期平均Hb为10.96 g/dl(95%CI 10.84-11.07),组间差异0.09 g/dl(95%CI -0.07-0.26),确立非劣效。
- 两组近90%受试者平均Hb维持在目标范围内。
- 与达依泊汀α相比,恩那度司他降低铁调素和铁蛋白,升高总铁结合力。
- 不良事件发生率:恩那度司他65.4%,达依泊汀α 82.6%,组间无明显差异。
临床怎么用
- 恩那度司他可作为非透析CKD贫血患者口服替代达依泊汀α的治疗选择,需每4周调整剂量维持Hb 10-12 g/dl。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that might be a new therapeutic approach for managing anemia in patients with chronic kidney disease (CKD). We evaluated the efficacy (noninferiority to darbepoetin alfa [DA]) and safety of enarodustat in Japanese anemic patients with CKD not requiring dialysis. METHODS: Erythropoiesis-stimulating agent (ESA)-naïve patients and ESA-treated patients were randomized at a 1:1 ratio to receive enarodustat orally once daily or DA subcutaneously every 2 or 4 weeks for 24 weeks, respectively. Subjects in each arm had dose adjustments every 4 weeks to maintain their hemoglobin (Hb) level within the target range (10 to 12 g/dl). The primary endpoint was the difference in the mean Hb level between arms during the evaluation period defined as weeks 20 to 24 (noninferiority margin: -0.75 g/dl). RESULTS: The mean Hb level during the evaluation period in the enarodustat arm was 10.96 g/dl (95% confidence interval [CI]: 10.84 to 11.07 g/dl) with a difference of 0.09 g/dl (95% CI: -0.07 to 0.26 g/dl) between arms, establishing its noninferiority to DA. Nearly 90% of subjects in both arms maintained a mean Hb level within the target range. Compared with DA, enarodustat was associated with decreased hepcidin and ferritin, and increased total iron-binding capacity. There were no apparent differences in the incidence of adverse events between arms (65.4% [enarodustat], 82.6% [DA]). CONCLUSIONS: The efficacy of enarodustat was comparable to DA in anemic patients with CKD not requiring dialysis. No new safety concerns were identified compared with DA.
引用
- Akizawa T, Nangaku M, Yamaguchi T, et al. A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. Kidney Int Rep. 2021. PMID: 34307978. doi:10.1016/j.ekir.2021.04.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。